KR920009399A - 면역 억제 활성을 갖는 약제를 제조하기 위한 크산틴의 용도 - Google Patents
면역 억제 활성을 갖는 약제를 제조하기 위한 크산틴의 용도 Download PDFInfo
- Publication number
- KR920009399A KR920009399A KR1019910021768A KR910021768A KR920009399A KR 920009399 A KR920009399 A KR 920009399A KR 1019910021768 A KR1019910021768 A KR 1019910021768A KR 910021768 A KR910021768 A KR 910021768A KR 920009399 A KR920009399 A KR 920009399A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- mammal
- medicament
- general formula
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title claims description 6
- 229940075420 xanthine Drugs 0.000 title claims description 3
- 239000003814 drug Substances 0.000 title claims 7
- 230000001506 immunosuppresive effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 20
- 241000124008 Mammalia Species 0.000 claims 8
- 210000004698 lymphocyte Anatomy 0.000 claims 8
- 230000004913 activation Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000005188 oxoalkyl group Chemical group 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 229960001476 pentoxifylline Drugs 0.000 claims 1
- 230000002457 bidirectional effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62048090A | 1990-11-30 | 1990-11-30 | |
| US07/620,480 | 1990-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR920009399A true KR920009399A (ko) | 1992-06-25 |
Family
ID=24486121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019910021768A Withdrawn KR920009399A (ko) | 1990-11-30 | 1991-11-29 | 면역 억제 활성을 갖는 약제를 제조하기 위한 크산틴의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0490181A1 (enExample) |
| JP (1) | JPH06100450A (enExample) |
| KR (1) | KR920009399A (enExample) |
| CA (1) | CA2056723A1 (enExample) |
| HU (1) | HUT59825A (enExample) |
| IE (1) | IE914163A1 (enExample) |
| IL (1) | IL100195A0 (enExample) |
| PT (1) | PT99659A (enExample) |
| TW (1) | TW205507B (enExample) |
| ZA (1) | ZA919438B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3566719B2 (ja) * | 1991-05-24 | 2004-09-15 | フレッド ハッチンソン キャンサー リサーチ センター | 外来性刺激に対する細胞性応答の調整 |
| DE4411660A1 (de) * | 1994-04-05 | 1995-10-12 | Hoechst Ag | Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung |
| DE4430127A1 (de) * | 1994-08-25 | 1996-03-14 | Hoechst Ag | Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat |
| DE4430128A1 (de) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
| US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| ATE234099T1 (de) * | 1998-04-24 | 2003-03-15 | Leuven K U Res & Dev | Immununterdrückende effekte von 8 substituierten xanthinderivaten |
| US6930101B1 (en) | 1999-05-17 | 2005-08-16 | The Regents Of The University Of California | Thiazolopyrimidines useful as TNFα inhibitors |
| US7253176B1 (en) | 2000-05-04 | 2007-08-07 | K.U. Leuven Research & Development | Immunosuppressive effects of 8-substituted xanthine derivatives |
| JP5567503B2 (ja) | 2008-02-29 | 2014-08-06 | コンサート ファーマシューティカルズ インコーポレイテッド | 置換キサンチン誘導体 |
| US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| JP2013503883A (ja) | 2009-09-02 | 2013-02-04 | コンサート ファーマシューティカルズ インコーポレイテッド | 置換キサンチン誘導体 |
| EP2611807A2 (en) | 2010-09-01 | 2013-07-10 | Concert Pharmaceuticals Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione |
| WO2013013052A1 (en) | 2011-07-19 | 2013-01-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| CN104364255A (zh) | 2012-04-13 | 2015-02-18 | 康塞特医药品有限公司 | 取代的黄嘌呤衍生物 |
| WO2013159006A1 (en) | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione |
| US9549869B2 (en) | 2012-06-29 | 2017-01-24 | Hill-Rom Canado Respiratory Ltd. | Wearable thorax percussion device |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0063827B1 (fr) * | 1980-05-02 | 1985-08-14 | Societe Des Produits Nestle S.A. | 1-Isopropyl- et 1-isobutyl-3,7-diméthylxanthine comme médicaments |
| IL100533A (en) * | 1986-12-31 | 1994-05-30 | Hoechst Roussel Pharma | Pharmaceutical preparations containing a history of xanthine for VIH treatment and disease states |
| US4965271A (en) * | 1986-12-31 | 1990-10-23 | Hoechst Roussel Pharmaceuticals, Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
| GB8918297D0 (en) * | 1989-08-10 | 1989-09-20 | Beecham Group Plc | Novel treatment |
-
1991
- 1991-11-28 IL IL100195A patent/IL100195A0/xx unknown
- 1991-11-28 EP EP91120425A patent/EP0490181A1/en not_active Withdrawn
- 1991-11-29 JP JP3316210A patent/JPH06100450A/ja active Pending
- 1991-11-29 HU HU913721A patent/HUT59825A/hu unknown
- 1991-11-29 IE IE416391A patent/IE914163A1/en not_active Application Discontinuation
- 1991-11-29 ZA ZA919438A patent/ZA919438B/xx unknown
- 1991-11-29 CA CA002056723A patent/CA2056723A1/en not_active Abandoned
- 1991-11-29 KR KR1019910021768A patent/KR920009399A/ko not_active Withdrawn
- 1991-11-29 PT PT99659A patent/PT99659A/pt not_active Application Discontinuation
-
1992
- 1992-03-06 TW TW081101708A patent/TW205507B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0490181A1 (en) | 1992-06-17 |
| TW205507B (enExample) | 1993-05-11 |
| IL100195A0 (en) | 1992-08-18 |
| HU913721D0 (en) | 1992-02-28 |
| HUT59825A (en) | 1992-07-28 |
| CA2056723A1 (en) | 1992-05-31 |
| IE914163A1 (en) | 1992-06-03 |
| ZA919438B (en) | 1992-08-26 |
| PT99659A (pt) | 1992-10-30 |
| JPH06100450A (ja) | 1994-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920009399A (ko) | 면역 억제 활성을 갖는 약제를 제조하기 위한 크산틴의 용도 | |
| DE69116503D1 (de) | Aminoglycosid-Zusammensetzung mit wesentlich verminderter Nephrotoxizität | |
| AU698419B2 (en) | A novel purine derivative | |
| IL88656A (en) | Pharmaceutical formulations containing 1,3-disubstituted-7- (oxohydrocarbyl) xanthine derivatives for inhibiting the activity of leukocyte- derived cytokines | |
| KR920009398A (ko) | 사람의 이인자형 이식반응 영향을 억제하는데 효과적인 약제를 제조하기 위한 크산틴의 용도 | |
| KR910004591A (ko) | 헤테로 고리 화합물 | |
| PT87322A (pt) | Novel 11-aryloestrane and 11-arylpregnane derivates | |
| KR920009397A (ko) | 사람 레트로바이러스의 복제를 억제하는데 효과적인 약제를 제조하기 위한 크산틴의 용도 | |
| KR890014107A (ko) | 백금 화학 요법약제 | |
| IL91913A0 (en) | Fluorosubstituted benzene derivatives,processes for the preparation thereof and diagnostic compositions containing the same | |
| KR910004557A (ko) | 2,4,6-치환 페놀 유도체 | |
| KR910700244A (ko) | 테트라알킬피페리디닐-치환된 우라실 유도체 및 이의 자외선 안정화제로서의 용도 | |
| KR840000578A (ko) | 포스포리피드 유도체의 제조방법 | |
| KR910004620A (ko) | 위궤양 치료제 | |
| KR870002118A (ko) | 벤질아민 유도체 및 그 제조방법 | |
| AU3873189A (en) | 5-substituted uridine derivatives and intermediates for their preparation | |
| KR900004335A (ko) | 간질환 치료제 | |
| ATE77744T1 (de) | Verwendung von pyrrothinderivaten. | |
| ATE61352T1 (de) | 4-hydroxy-4-(substituierte alkenyl)cyclohexancarbons|ure. | |
| KR860008978A (ko) | 세미카바지드 유도체의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19911129 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |